Literature DB >> 10595527

Intrabody construction and expression III: engineering hyperstable V(H) domains.

P Wirtz1, B Steipe.   

Abstract

The folding of immunoglobulin domains requires the formation of a conserved structural disulfide. Therefore, as a general rule, they cannot be functionally expressed in the reducing environment of the cellular cytoplasm. We have previously reported that stability engineering can lead to the cytoplasmic expression of functional immunoglobulin V(L) domains. Here we apply rational stability engineering by consensus sequence analysis to V(H) domains. Isolated V(H) domains tend to aggregate more easily than V(L) domains; they do not refold quantitatively and are generally more difficult to handle in vitro. To overcome these problems, we successfully predicted and experimentally verified several stabilizing point mutations in the V(H) domain of a designed, catalytic Fv fragment. The effect of single mutations was additive, and they could be combined in a prototype domain with significantly improved stability against chemical denaturation and a 20-fold increased half time of irreversible thermal denaturation, at physiological temperature. This stabilized, isolated V(H) domain could be expressed solubly in the reducing cellular cytoplasm of Escherichia coli, at a yield of approximately 1.2 mg/L of shake flask culture. It remains fully functional, as evidenced by the successful reconstitution of an esterolytic Fv fragment with the V(L) domain. This success provides further evidence that consensus sequence engineering is a rational, plannable route to the construction of intrabodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595527      PMCID: PMC2144211          DOI: 10.1110/ps.8.11.2245

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  24 in total

1.  Intrabody construction and expression. II. A synthetic catalytic Fv fragment.

Authors:  E C Ohage; P Wirtz; J Barnikow; B Steipe
Journal:  J Mol Biol       Date:  1999-09-03       Impact factor: 5.469

2.  The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli.

Authors:  R Glockshuber; T Schmidt; A Plückthun
Journal:  Biochemistry       Date:  1992-02-11       Impact factor: 3.162

3.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli.

Authors:  E S Ward; D Güssow; A D Griffiths; P T Jones; G Winter
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

4.  Sequence statistics reliably predict stabilizing mutations in a protein domain.

Authors:  B Steipe; B Schiller; A Plückthun; S Steinbacher
Journal:  J Mol Biol       Date:  1994-07-15       Impact factor: 5.469

5.  Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region.

Authors:  A L Bothwell; M Paskind; M Reth; T Imanishi-Kari; K Rajewsky; D Baltimore
Journal:  Cell       Date:  1981-06       Impact factor: 41.582

6.  Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli.

Authors:  A Skerra
Journal:  Gene       Date:  1994-12-30       Impact factor: 3.688

7.  Conformational stability and activity of ribonuclease T1 with zero, one, and two intact disulfide bonds.

Authors:  C N Pace; G R Grimsley; J A Thomson; B J Barnett
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

8.  Crystal structure of a catalytic antibody with a serine protease active site.

Authors:  G W Zhou; J Guo; W Huang; R J Fletterick; T S Scanlan
Journal:  Science       Date:  1994-08-19       Impact factor: 47.728

9.  Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase (TrxB).

Authors:  K Proba; L Ge; A Plückthun
Journal:  Gene       Date:  1995-07-04       Impact factor: 3.688

10.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

View more
  13 in total

1.  The design of a hyperstable mutant of the Abp1p SH3 domain by sequence alignment analysis.

Authors:  A Rath; A R Davidson
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

2.  De novo production of diverse intracellular antibody libraries.

Authors:  Tomoyuki Tanaka; Grace T Y Chung; Alan Forster; M Natividad Lobato; Terence H Rabbitts
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

3.  Functional aspects of co-variant surface charges in an antibody fragment.

Authors:  Nicolas Hugo; Virginie Lafont; Mervyn Beukes; Danièle Altschuh
Journal:  Protein Sci       Date:  2002-11       Impact factor: 6.725

Review 4.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

5.  Energetics of aliphatic deletions in protein cores.

Authors:  Marta Bueno; Luis A Campos; Jorge Estrada; Javier Sancho
Journal:  Protein Sci       Date:  2006-08       Impact factor: 6.725

Review 6.  Protein stability by number: high-throughput and statistical approaches to one of protein science's most difficult problems.

Authors:  Thomas J Magliery; Jason J Lavinder; Brandon J Sullivan
Journal:  Curr Opin Chem Biol       Date:  2011-04-15       Impact factor: 8.822

7.  A strategy for adenovirus vector targeting with a secreted single chain antibody.

Authors:  Joel N Glasgow; Galina Mikheeva; Victor Krasnykh; David T Curiel
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

8.  Modification of the kinetic stability of immunoglobulin G by solvent additives.

Authors:  Jonas V Schaefer; Erik Sedlák; Florian Kast; Michal Nemergut; Andreas Plückthun
Journal:  MAbs       Date:  2018-04-25       Impact factor: 5.857

9.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation.

Authors:  Tomoyuki Tanaka; Terence H Rabbitts
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

Review 10.  Intrabody and Parkinson's disease.

Authors:  Chun Zhou; Serge Przedborski
Journal:  Biochim Biophys Acta       Date:  2008-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.